{"result": "(\"entity\"<|>ALOPURINOL<|>PERSON<|>Allopurinol is a medication used to manage uric acid levels and is mentioned in the context of measuring urinary orotates in metabolic assessments.)\n##\n(\"entity\"<|>PHENYLBUTIRATE<|>PERSON<|>Phenylbutyrate is a medication used to reduce ammonia levels in patients with urea cycle disorders, transforming into phenylacetate.)\n##\n(\"entity\"<|>PHENYLACETATE<|>PERSON<|>Phenylacetate is a compound formed from phenylbutyrate that helps in the elimination of ammonia.)\n##\n(\"entity\"<|>HYPERAMONIEMIA<|>EVENT<|>Hyperammonemia is a medical condition characterized by elevated ammonia levels in the blood, often requiring urgent treatment.)\n##\n(\"entity\"<|>NUTRITIONAL SUPPORT<|>EVENT<|>Nutritional support refers to dietary management strategies employed to assist patients with metabolic disorders.)\n##\n(\"entity\"<|>PROTEIN RESTRICTION<|>EVENT<|>Protein restriction is a dietary intervention used in managing metabolic disorders to prevent catabolism and control ammonia levels.)\n##\n(\"entity\"<|>LIVER TRANSPLANT<|>EVENT<|>Liver transplant is a surgical procedure considered for patients with severe metabolic disorders, particularly when other treatments fail.)\n##\n(\"relationship\"<|>ALOPURINOL<|>HYPERAMONIEMIA<|>Allopurinol is used in the context of managing conditions that may lead to hyperammonemia<|>4)\n##\n(\"relationship\"<|>PHENYLBUTIRATE<|>HYPERAMONIEMIA<|>Phenylbutyrate is administered to treat hyperammonemia by facilitating ammonia elimination<|>8)\n##\n(\"relationship\"<|>PHENYLACETATE<|>HYPERAMONIEMIA<|>Phenylacetate is a product of phenylbutyrate that aids in reducing hyperammonemia<|>8)\n##\n(\"relationship\"<|>NUTRITIONAL SUPPORT<|>PROTEIN RESTRICTION<|>Nutritional support often involves protein restriction to manage metabolic disorders<|>6)\n##\n(\"relationship\"<|>LIVER TRANSPLANT<|>HYPERAMONIEMIA<|>Liver transplant may be necessary in severe cases of hyperammonemia when other treatments are ineffective<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: pues se conjuga con Gly, dando hipurato, que eli-\nenfermedad o déficit proteico. También se miden los                            mina amonio por la orina; se debe administrar\nniveles plasmáticos de Gln (alta > 800 μmol/l), argini-                        folato, que se consume en la producción de Gly a\nna (Arg, mantener en 50-200               μmol/l), citrulina (alta             partir de serina. El benzoato produce un incre-\n> 100 μmol/l, muy alta > 250) y proteínas viscerales y                         mento de la eliminación de potasio por la orina,\nniveles urinarios de orotato tras sobrecarga con alopu-                        que puede originar hipocaliemia y alcalosis meta-\nrinol (alto >3 μmol/mol de creatinina), indicando estos                        bólica, así como náuseas, vómitos e irritabilidad;\núltimos un aporte deficiente de Arg o un control insu-                         la sobredosificación puede desencadenar una cri-\nficiente si se encuentran 5-10 veces mayores que el lí-                        sis hiperamoniémica.\nmite superior de la normalidad.                                                Se puede administrar fenilbutirato, a dosis de\n                                                                               250-500 mg/kg día, según sea combinado con\n5.4.    Tratamiento dietético-nutricional                                      benzoato o no, que se transforma en fenilaceta-\n                                                                               to, el cual se conjuga con Gln dando fenilacetil-\n   El aporte calórico de los pacientes afectados debe ser                      Gln; se elimina el doble de amonio por cada fenil-\nun 25-50% superior al calculado en sanos para evitar el                        butirato; también es posible emplear fenilacetato\ncatabolismo proteico y favorecer la formación de ce-                           directamente. Los efectos adversos son similares a\ntoácidos, pero evitando sobrepeso. Debe realizarse una                         los de benzoato. El N-carbamilglutamato se da\nrestricción proteica variable según el tipo y grado de                         en la deficiencia de N-acetilglutamatosintetasa\nafectación y la edad (mayores necesidades en los pri-                          (NAGS) pues activa la CPS, derivándose a esta en-\nmeros seis meses de vida), asegurando la ingesta de                            trada al ciclo los restos procedentes de glutama-\nPNAVB; limitar el aporte de Arg en argininemia. En las                         to; las dosis empleadas son de 100-200 mg/kg/\nformas más graves (sobre todo déficit de CPS y OTC) y                          día en las formas agudas neonatales y 20-30 mg/\ncuando       hay    anorexia     importante,       administrar      un         kg/día en las tardías.\n25-50% como mezcla de aa esenciales hasta 0,7 g/kg                          c. Trasplante hepático. En casos graves de deficien-\ndía, repartido en dos a tres tomas; para ello se em-                           cia de OTC y CPS y si hay episodios recurrentes de\nplean: Vitaflo EAA®, UCD 1 ®, UCD 2 ®, Dialamine®                     y        hiperamoniemia a pesar de tratamiento adecua-\nEssential Amino AcidMix®. En caso de empeoramiento                             do o si no es posible seguir tratamiento dieté-\nmetabólico por ayuno prolongado o aumento del cata-                            tico-nutricional, incluir en programa de trasplante\nbolismo proteico, es preciso reducir la ingesta proteica                       de forma precoz. Al contrario, conforme crecen\na la mitad o suspenderla, ingresando al paciente si no                         los pacientes con deficiencias de ASS o ASL, me-\npresenta tolerancia oral. Es necesario emplear suple-                          jora su tolerancia a proteínas. Tras el trasplante, el\nmentos de vitaminas y minerales por el posible déficit                         control metabólico es precoz y hace innecesarias\ntras la restricción proteica, con una fórmula del tipo                         restricciones o medicación, salvo en algunos ca-\nEnergivit®.                                                                    sos, la suplementación de Arg.\n5.5.    Otros tratamientos26, 27                                         5.6.   Tratamiento de las crisis\n   a.  Aporte de productos deficitarios. Se debe apor-                          hiperamoniémicas26, 27\n       tar arginina a dosis de 100-170 mg/kg día en                         En primer lugar, como en todas las situaciones de\n       todos los casos salvo en la argininemia, ya que                   emergencia, es preciso asegurar la vía aérea, incluso\n---\n                                                 Tema 18.     Soporte nutricional en metabolopatías de los aminoácidos…                    317\n\n\n\ncon ventilación mecánica; controlar también la presión                      6.2.   Manifestaciones clínicas\nintracraneal. Se debe aportar su\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>GLY<|>PERSON<|>Gly is a compound involved in metabolic processes, particularly in the formation of hipurato and the elimination of ammonia through urine.)\n##\n(\"entity\"<|>ARG<|>PERSON<|>Arg is an amino acid that is monitored in patients, with recommended plasma levels maintained between 50-200 μmol/l.)\n##\n(\"entity\"<|>CPS<|>PERSON<|>CPS refers to Carbamoyl Phosphate Synthetase, an enzyme involved in the urea cycle, which is critical for ammonia detoxification.)\n##\n(\"entity\"<|>OTC<|>PERSON<|>OTC stands for Ornithine Transcarbamylase, an enzyme that plays a role in the urea cycle and is significant in metabolic disorders.)\n##\n(\"entity\"<|>NAGS<|>PERSON<|>NAGS is N-acetylglutamate synthetase, an enzyme that activates CPS and is important in the urea cycle.)\n##\n(\"entity\"<|>VITAFLO EAA<|>ORGANIZATION<|>Vitaflo EAA is a product used for dietary management in patients with metabolic disorders, providing essential amino acids.)\n##\n(\"entity\"<|>UCD 1<|>ORGANIZATION<|>UCD 1 is a dietary supplement used in the treatment of urea cycle disorders.)\n##\n(\"entity\"<|>UCD 2<|>ORGANIZATION<|>UCD 2 is another dietary supplement aimed at managing urea cycle disorders.)\n##\n(\"entity\"<|>DIALAMINE<|>ORGANIZATION<|>Dialamine is a product used to provide essential amino acids in dietary management for metabolic disorders.)\n##\n(\"entity\"<|>ENERGIVIT<|>ORGANIZATION<|>Energivit is a nutritional formula used to supplement vitamins and minerals in patients with dietary restrictions.)\n##\n(\"relationship\"<|>GLY<|>ARG<|>Gly is involved in the production of Arg and is crucial for metabolic processes related to amino acids<|>7)\n##\n(\"relationship\"<|>CPS<|>NAGS<|>NAGS activates CPS, which is essential for the urea cycle and ammonia detoxification<|>8)\n##\n(\"relationship\"<|>OTC<|>CPS<|>OTC works in conjunction with CPS in the urea cycle, both being critical for ammonia metabolism<|>8)\n##\n(\"relationship\"<|>VITAFLO EAA<|>UCD 1<|>Vitaflo EAA is used alongside UCD 1 for dietary management in patients with urea cycle disorders<|>6)\n##\n(\"relationship\"<|>UCD 1<|>UCD 2<|>UCD 1 and UCD 2 are both dietary supplements used for managing urea cycle disorders<|>5)\n##\n(\"relationship\"<|>DIALAMINE<|>VITAFLO EAA<|>Dialamine and Vitaflo EAA are both products used to provide essential amino acids in dietary management<|>6)\n##\n(\"relationship\"<|>ENERGIVIT<|>VITAFLO EAA<|>Energivit is used to supplement vitamins and minerals in patients who are also using Vitaflo EAA<|>5)\n<|COMPLETE|>"}]}